Your SlideShare is downloading. ×
The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research

281
views

Published on

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
281
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. ANGIO 2013 The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Cancer Research January 31–February 2, 2013 Hyatt Regency La Jolla • 3777 La Jolla Village Drive • San Diego, California www.antiangio2013.com For Information and Poster Submission Form
  • 2. Program Overview Angiogenesis is an essential process in the growth of neoplasms and progression to metastasis. The angiogenic pathway is orchestrated by a range of pro- and anti-angiogenic factors that ultimately lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth factor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in this process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal antibody directed against VEGF – the first anti-angiogenic systemic drug to treat cancer patientsvalidated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid approach to control tumor growth. This success has driven the search for new anti-angiogenic agents. For example, small-molecule multikinase inhibitors that target VEGF receptors have recently demonstrated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an increasing variety of molecular tumor features are in clinical development. More recently, studies of powerful new genetic and cell biological approaches have provided unprecedented insights into how various molecular are pivotal to tumor growth and survival. As a consequence, a number of new angiogenic molecules, such as neuropilins, Tie-2, and Notch ligand delta-like 4, have emerged as promising targets. Since its inception over 4 decades ago, investigators in the field of tumor angiogenesis research have made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, and the next decade promises to be an exciting and productive time. This annual state-of-the-art symposium is designed to continue the dialogue and interaction between research and clinical investigators by reviewing the current scientific understanding of vascular biology and angiogenesis. In addition, this symposium provides a forum for presenting the most current preclinical and clinical data on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in colorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, hepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance pathways will be addressed and controversies in the field will be highlighted. Educational Objectives After attending the symposium, participants should be able to • Define angiogenesis and its relevance to the treatment of cancer (Knowledge); • Outline the rationale for the development of anti-angiogeneic agents, and explain why angiogenic signaling pathways are targets for inhibition (Knowledge); • Summarize data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities, which will ultimately assist the healthcare provider to make appropriate clinical decisions (Knowledge, Competence, Performance, Patient Outcomes); Target Audience This symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice. Educational Methods Lectures – Panel Discussions – Question and Answer – Poster Session Evaluation A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. Accreditation/Credit Designation The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME Certificates and Attendance Verification Certificates Certificates awarding AMA PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations. POSTER SUBMISSION/ SESSION: The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions All symposium participants, including members of industry, are encouraged to present research data as part of the poster session. The deadline for submitting poster applications is Friday, December 14, 2012. Please check the website for more information and the submission form at www.antiangio2013.com. Planning Committee Lee M. Ellis, MD George W. Sledge, Jr., MD Robert S. Kerbel, PhD Helen X. Chen, MD Professor of Surgery and Cancer Biology William C. Liedtke, Jr., Chair in Cancer Research The University of Texas MD Anderson Cancer Center Houston, Texas Canada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic Therapy University of Toronto Professor, Molecular and Cellular Biology Research Sunnybrook Health Sciences Centre/Odette Cancer Centre Toronto, Ontario, Canada Ballve-Lantero Professor of Oncology Co-Director, Breast Cancer Program Indiana University Melvin and Ben Simon Cancer Center Indianapolis, Indiana Senior Investigator in Cancer Therapy Evaluation Program National Cancer Institute Rockville, Maryland Axel Grothey, MD Professor of Oncology Division of Medical Oncology Mayo Clinic Division of Medical Oncology Rochester, Minnesota
  • 3. Program Wednesday, January 30, 2013 3:00–7:00 p.m. Registration Thursday, January 31, 2013 7:30–8:00 a.m. Registration/Continental Breakfast Session I: Basic Biology and Preclinical Data Moderator: Lee M. Ellis, MD; Robert S. Kerbel, PhD 8:00–8:30 8:30–8:55 8:55–9:20 9:20–9:45 9:45–10:10 Opening Remarks/Overview Lee M. Ellis, MD Combinatorial Targeting of Endothelial Growth Factors and Receptors Kari Alitalo, MD, PhD Tumor Hypoxia: Is Targeting HIF a Viable Approach? M. Celeste Simon, PhD Metronomic Chemotherapy with Anti-Angiogenic Drugs: An Update Robert S. Kerbel, PhD Resistance to VEGF-Targeted Therapies TBD 10:10–10:30 Break 10:30–10:55 Anti-Angiogenic Agents Stimulate Breast Cancer Stem Cells via Generation of Tumor Hypoxia Max S. Wicha, MD 10:55–11:10 Abstract #1 11:10–11:35 The Role of SDF-1/CXCR4 Signaling in Angiogenesis Martin Brown, DPhil 11:35–Noon Oscillation of Immune Cells in Response to Anti-Angiogenic Therapy Gabriele Bergers, PhD Noon–1:00 p.m. Lunch Session II: Biomarkers and Imaging Moderator: Robert S. Kerbel, PhD Predictive Biomarkers: VEGF Amplifications and Host Polymorphisms Bryan P. Schneider, MD 1:25–1:50 Predictive Biomarkers: Imaging and Circulating VEGF Gordon Jayson, MD, PhD 1:50–2:05 Abstract #2 2:05–2:30 Standardizing Imaging Criteria to Assess the Effect of Anti VEGF Therapy in Brain Tumors Bradley J. Erickson, MD, PhD 2:30–2:55 The FDA Pre-IDE Process: Lessons Learned for Integral Markers J. Milburn Jessup, MD 2:55–3:15 Break 3:15–3:45 Panel Discussion: Implementation of Biomarkers Moderator: Lee M. Ellis, MD Panelists: S. Gail Eckhardt, MD; Bradley J. Erickson, MD, PhD; Axel Grothey, MD; Gordon Jayson, MD, PhD; J. Milburn Jessup, MD; Bryan P. Schneider, MD 3:45–5:30 p.m. Poster Reception 1:00–1:25 Friday, February 1, 2013 7:30–8:00 a.m. Registration/Continental Breakfast Session III: Controversies and New Horizons Moderators: Axel Grothey, MD; George W. Sledge, Jr., MD 8:00–8:05 Introduction George W. Sledge, Jr., MD 8:05–8:25 Is RECIST Still Relevant in the Era of VEGF Inhibition Through Multiples Lines of Therapy? Implications for Clinical Trial Design in All Malignancies Axel Grothey, MD 8:25– 8:50 Patient Derived Xenograft Models: Are They Appropriate For Anti-Angiogenic and Microenvironment Therapies? S. Gail Eckhardt, MD 8:50–9:15 From the Laboratory to the Labrador: Spontaneous Canine Cancer as a Model for Anti-Angiogenic Drug Development Douglas H. Thamm, VMC, DACVIM 9:15–9:40 Promise and Pitfalls of Anti-Angiogenic Therapy in the Adjuvant Setting Daniel F. Hayes, MD
  • 4. 9:40–10:00 Break Session IV: Early Drug Development Moderators: Helen X. Chen, MD; George W. Sledge, Jr., MD 10:00–10:15 Early Drug – Phase I Michael S. Gordon, MD 10:15–10:30 Early Drug – Phase I Lee S. Rosen, MD 10:30–10:45 10:45–11:00 11:00–11:25 Saturday, February 2, 2013 7:30–8:00 a.m. Registration/Continental Breakfast Session V: Clinical Trial Results Moderator: Axel Grothey, MD 8:00–8:05 Introduction Axel Grothey, MD Abstract #3 8:05–8:30 A Phase I Clinical Trial of VX15/2503, A Novel Humanized IgG4 Anti-SEMA4D Antibody, In Patients With Advanced Solid Tumors Amita Patnaik, MD Clinical Overview and Perspectives on Anti-Angiogenic Therapy in CNS Tumors Patrick Y. Wen, MD The Role of CTEP in the Development of Angiogenesis Inhibitors Helen X. Chen, MD 8:30–8:55 Antio-Angiogenic Therapy for the Treatment of Neuroendocrine Tumors James C. Yao, MD 11:30–12:30 p.m. Lunch 8:55–9:10 Abstract #5 9:10–9:35 Anti-Angiogenic Therapy for the Treatment of Lung Cancer Corey J. Langer, MD Session V: Clinical Trial Results 9:35–10:00 Anti-Angiogenic Therapy for the Treatment of Breast Cancer George W. Sledge, Jr., MD 10:00 Closing Remarks Moderator: Helen X. Chen, MD; Michael S. Gordon, MD Anti-Angiogenic Therapy for the Treatment of Hepatocellular Carcinoma Ghassan K. Abou-Alfa, MD 12:55–1:20 Anti-Angiogenic Therapy for the Treatment of Sarcoma Gary K. Schwartz, MD 1:20–1:45 Anti-Angiogenic Therapy for the Treatment of Ovarian Cancer Gordon Jayson, MD, PhD 12:30-12:55 1:45–2:05 Break Anti-Angiogenic Therapy for the Treatment of Colorectal Cancer Charles D. Blanke, MD 2:30–2:45 Abstract #4 2:45–3:10 Anti-Angiogenic Therapy for the Treatment of Renal Cell Carcinoma Eric Jonasch, MD 3:10–3:35 Vascular Disrupting Agents Gordon Rustin, MD 2:05–2:30 3:35 Adjourn 10:15 Adjourn
  • 5. Faculty Ghassan K. Abou-Alfa, MD Associate Attending Professor Memorial Sloan-Kettering Cancer Center New York, New York Kari Alitalo, MD, PhD Research Professor of the Academy of Finland Biomedicum Helsinki University of Helsinki Helsinki, Finland Gabriele Bergers, PhD Professor Brain Tumor Research Center University of California San Francisco San Francisco, California Charles D. Blanke, MD Vice-President Systemic Therapy British Columbia Cancer Agency Professor & Chief, Medical Oncology University of British Columbia Vancouver, British Columbia Canada Martin Brown, DPhil Professor Stanford University Division of Radiation and Cancer Biology Palo Alto, California Helen X. Chen, MD Senior Investigator in Cancer Therapy Evaluation Program National Cancer Institute Rockville, Maryland S. Gail Eckhardt, MD Professor and Division Head Medical Oncology Stapp Harlow Chair in Cancer Research University of Colorado Denver Aurora, Colorado Lee M. Ellis, MD Professor of Surgery and Cancer Biology William C. Liedtke, Jr. Chair in Cancer Research The University of Texas MD Anderson Cancer Center Houston, Texas Bradley J. Erickson, MD, PhD Associate Professor of Radiology and Informatics Mayo Medical School Mayo Clinic Rochester, Minnesota Michael S. Gordon, MD Medical Oncology Pinnacle Oncology Hematology Scottsdale, Arizona Axel Grothey, MD Professor of Oncology Mayo Clinic College of Medicine Rochester, Minnesota Daniel F. Hayes, MD Clinical Director Breast Medical Oncology Program Stuart B. Padnos Professor in Breast Cancer University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Gordon Jayson, MD, PhD Professor of Medical Oncology The University of Manchester Withington, Manchester United Kingdom J. Milburn Jessup, MD Chief, Diagnostics Evaluation Branch Cancer Diagnosis Program National Cancer Institute Rockville, Maryland Eric Jonasch, MD Associate Professor of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Robert S. Kerbel, PhD Canada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic Therapy University of Toronto Professor, Molecular and Cellular Biology Research Sunnybrook Health Sciences Center/Odette Cancer Center Toronto, Ontario, Canada Corey J. Langer, MD Professor of Medicine University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, Pennsylvania Amita Patnaik, MD Associate Director of Clinical Reserarch START San Antonio, Texas Lee S. Rosen, MD Professor of Clinical Medicine Division of Hematology-Oncology University of California Los Angeles, California Gordon Rustin, MD Director of Medical Oncology Mount Vernon Cancer Centre Northwood, Middlesex United Kingdom Bryan P. Schneider, MD Associate Professor Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana Gary K. Schwartz, MD Chief Melanoma and Sarcoma Service Attending Physician Memorial Sloan-Kettering Cancer Center New York, New York M. Celeste Simon, PhD Professor of Cell and Developmental Biology University of Pennsylvania Howard Hughes Medical Institute Philadelphia, Pennsylvania George W. Sledge, Jr., MD Ballve-Lantero Professor of Oncology Co-Director, Breast Cancer Program Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana Douglas H. Thamm, VMC, DACVIM Assistant Professor and Barbara Cox Anthony Chair in Oncology Director of Clinical Research The Animal Cancer Center Colorado State University Cancer Center Fort Collins, Colorado Patrick Y. Wen, MD Professor of Neurology Harvard Medical School Director, Center for Neuro-Oncology Dana Farber Cancer Institute Boston, Massachusetts Max S. Wicha, MD Professor Department of Internal Medicine Director University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan James C. Yao, MD Associate Professor GI Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Registration Information On-site registration will be open from 3:00-7:00 p.m. on Wednesday, January 30, 2013, and at 7:30 a.m. on Thursday, January 31. The conference will begin at 8:00 a.m. on Thursday, January 31, and adjourn at 10:15 a.m. on Saturday, February 2. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees. The deadline for advance registration is January 16, 2013. There are three ways to register: • Mail to: CME/Conference Management–Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439 • Fax to: 713-794-1724 • On-line at www.mdanderson.org/conferences We accept the following forms of payment: • Check (payable through U.S. banks only) • Money Order • Credit Cards (MasterCard, VISA, and American Express) • Cash (on-site registration only) A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The full conference registration fee includes the tuition, breaks, lunch, and poster reception. Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 16, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
  • 6. Registration also available on-line www.antiangio2013.com ___________________________________ IDT Approver E-mail IDT Approver Name (First/Last) please print Authorized Signature REQUIRED for credit card or IDT MD Anderson Employee ID No. (REQUIRED) Department Chair should verify Trainee status by signing below: Expiration Date Credit Card Number or MD Anderson Interdepartmental Transfer (IDT) No. Credit Card Holder Name (First/Last) Credit Card Holder Billing Address & ZIP Code Trainees: 1 Postmarked by 1/16/13............ $ 100.00 1 Postmarked after 1/16/13........ $ 150.00 1 Trainee Submitting Poster..... $ 50.00 oAmerican Express oVISA oMasterCard Charge the following: 1 Postmarked by 1/16/13............. $ 275.00 1 Postmarked after 1/16/13......... $ 325.00 Phone (with area code) Emergency Contact E-mail Address REGISTRATION FEES Cell Phone (with area code) Fax (with area code) City State/Foreign Country/Zip or Mail Code Make check or money order payable to: The University of Texas MD Anderson Cancer Center Physician Specialty o Yes o No or fax to 713-794-1724 Department of CME/Conference Management–Unit 1381 The University of Texas MD Anderson Cancer Center PO Box 301439, Houston, TX 77230-1439 Highest Degree Daytime Phone (with area code) Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration. Street Photographing, audio taping and videotaping are prohibited. Institution Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth. Department (include box no.) The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. CONFERENCE REGISTRATION - 0597 The hotel is approximately 20 miles from the San Diego International Airport. Taxi rates are approximately $45 one way. MI Ground Transportation The 15th International Symposium on Anti-Angiogenic Therapy: • When you make reservations be sure to mention the MD Anderson 15th International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of $215.00 single or double occupancy. Please add 12.5% California state and local taxes. Reservations and deposits received after December 28, 2012 will be confirmed if space is available and at current hotel published guest room rates. First • The hotel reservations number is 858-552-1234. Last Name • Early hotel reservation is suggested. Recent Advances and Future Directions in Basic and Clinical Cancer Research, January 31–February 2, 2013 • A block of rooms has been reserved for conference attendees at the Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, California. ADDRESS TO: Accommodations The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Cancer Research Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs. THIS IS NOT A SELF-MAILER Special Assistance
  • 7. Department of CME/Conference Management - Unit 1381 The University of Texas MD Anderson Cancer Center # 176700/110501 PO Box 301439 Houston, TX 77230-1439 Non-Profit Org. U.S. Postage PAID Houston, TX Permit No. 7052